Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silo Pharma (SILO) Change in Accured Expenses (2019 - 2025)

Silo Pharma's Change in Accured Expenses history spans 7 years, with the latest figure at -$341558.0 for Q3 2025.

  • For Q3 2025, Change in Accured Expenses fell 22.84% year-over-year to -$341558.0; the TTM value through Sep 2025 reached -$324093.0, down 373.13%, while the annual FY2024 figure was $633007.0, 86.58% up from the prior year.
  • Change in Accured Expenses for Q3 2025 was -$341558.0 at Silo Pharma, down from -$123007.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $611165.0 in Q4 2024 and bottomed at -$470693.0 in Q1 2025.
  • The 5-year median for Change in Accured Expenses is $67721.0 (2022), against an average of $14439.5.
  • The largest YoY upside for Change in Accured Expenses was 331361.54% in 2023 against a maximum downside of 751.82% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $206651.0 in 2021, then plummeted by 31.98% to $140571.0 in 2022, then plummeted by 31.12% to $96819.0 in 2023, then surged by 531.24% to $611165.0 in 2024, then tumbled by 155.89% to -$341558.0 in 2025.
  • Per Business Quant, the three most recent readings for SILO's Change in Accured Expenses are -$341558.0 (Q3 2025), -$123007.0 (Q2 2025), and -$470693.0 (Q1 2025).